Our Molecular Genetics Unit is focused on understanding the genetic causes underlying neurodegenerative disorders, and developing new genetic-based biomarkers to aid in disease diagnosis and prognosis. To accomplish this, we use state-of-the-art genetic tools such as next-generation sequencing, ddPCR, etc. applied to patients that have been diagnosed and followed-up by our memory clinic team. We also collaborate actively with numerous international and national genomic consortiums aimed at revealing the genetic architecture of neurodegenerative disorders, including dementias, neuromuscular disorders such as ALS and Parkinson’s disease.